title: Combination treatment with resveratrol and sulforaphane induces apoptosis in human U251 glioma cells.
abstract: Resveratrol is a naturally occurring polyphenolic compound highly enriched in grapes, peanuts, red wine, and a variety of food sources. Sulforaphane belongs to the family of isothiocyanates and is highly enriched in cruciferous vegetables. Our previous study showed that resveratrol, when used at high concentrations, inhibited cell proliferation, caused the cell cycle arrest and induced apoptotic cell death in glioma cells. In the current study, we tested the effect of combination treatment with resveratrol and sulforaphane, when both were used at low concentrations, on cell proliferation, migration and death in human U251 glioma cells. Our study shows that combination treatment with resveratrol and sulforaphane inhibits cell proliferation and migration, reduces cell viability, induces lactate dehydrogenase release, decreases pro-survival Akt phosphorylation and increases caspase-3 activation. The use of combination of bioactive food components, such as resveratrol and sulforaphane, may be a viable approach for the treatment of glioma.
authors.affiliation: Department of Neurology, Henry Ford Hospital, Detroit, MI 48202, USA. hjiang1@hfhs.org
authors.forename: Hao
authors.initials: H
authors.lastname: Jiang
authors.forename: Xia
authors.initials: X
authors.lastname: Shang
authors.forename: Hongtao
authors.initials: H
authors.lastname: Wu
authors.forename: Grace
authors.initials: G
authors.lastname: Huang
authors.forename: Yiyang
authors.initials: Y
authors.lastname: Wang
authors.forename: Shaza
authors.initials: S
authors.lastname: Al-Holou
authors.forename: Subhash C
authors.initials: SC
authors.lastname: Gautam
authors.forename: Michael
authors.initials: M
authors.lastname: Chopp
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005910:Glioma / Q000473:pathology*; D006801:Humans; D017879:Isothiocyanates; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*; D013454:Sulfoxides; D013861:Thiocyanates / Q000494:pharmacology*
chemical_list: D017879:Isothiocyanates; D013267:Stilbenes; D013454:Sulfoxides; D013861:Thiocyanates; C016766:sulforaphane; D000077185:Resveratrol
references.citation: Cancer Res. 2005 Mar 1;65(5):2035-43
references.pmid: 15753404
references.citation: J Urol. 2002 Aug;168(2):748-55
references.pmid: 12131363
references.citation: Prostate. 2002 Sep 1;52(4):319-29
references.pmid: 12210493
references.citation: Mol Cancer. 2006 Oct 17;5:45
references.pmid: 17044934
references.citation: J Neurooncol. 1991 Oct;11(2):165-70
references.pmid: 1744684
references.citation: Int J Cancer. 2002 Apr 10;98(5):761-9
references.pmid: 11920648
references.citation: Mol Cancer Ther. 2007 Jan;6(1):334-45
references.pmid: 17237292
references.citation: Mol Carcinog. 2006 Jun;45(6):443-6
references.pmid: 16652377
references.citation: Apoptosis. 2000 Nov;5(5):415-8
references.pmid: 11256882
references.citation: Neurosci Lett. 2006 Oct 16;407(1):53-8
references.pmid: 16949208
references.citation: Cell Cycle. 2008 Apr 15;7(8):1020-35
references.pmid: 18414053
references.citation: Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2399-403
references.pmid: 1549603
references.citation: Cancer Lett. 2008 Oct 8;269(2):243-61
references.pmid: 18550275
references.citation: J Neurooncol. 2007 Feb;81(3):231-40
references.pmid: 17031560
references.citation: Int J Oncol. 2003 Jul;23(1):17-28
references.pmid: 12792772
references.citation: J Nutr. 2002 Jul;132(7):2076-81
references.pmid: 12097696
references.citation: Cancer Lett. 2008 Apr 8;262(1):10-8
references.pmid: 18164805
references.citation: Carcinogenesis. 2007 May;28(5):1058-66
references.pmid: 17183064
references.citation: Am J Clin Nutr. 2005 Jan;81(1 Suppl):284S-291S
references.pmid: 15640492
references.citation: Clin Cancer Res. 2002 Mar;8(3):893-903
references.pmid: 11895924
references.citation: Int J Oncol. 2004 May;24(5):1101-9
references.pmid: 15067331
references.citation: Environ Health Perspect. 1995 Nov;103 Suppl 8:165-70
references.pmid: 8741778
references.citation: Oncol Rep. 2007 Jul;18(1):181-7
references.pmid: 17549366
references.citation: Biochem Pharmacol. 2006 May 14;71(10):1397-421
references.pmid: 16563357
references.citation: J Cell Biochem. 1997 Aug 1;66(2):229-44
references.pmid: 9213224
references.citation: Mol Cancer Ther. 2006 May;5(5):1335-41
references.pmid: 16731767
references.citation: Mol Cancer Ther. 2006 Mar;5(3):575-85
references.pmid: 16546971
references.citation: Carcinogenesis. 2001 Oct;22(10):1633-9
references.pmid: 11577002
references.citation: Biomed Pharmacother. 2008 Nov;62(9):637-44
references.pmid: 18313257
references.citation: Clin Cancer Res. 2004 Mar 15;10(6):2190-202
references.pmid: 15041740
references.citation: J Nutr. 2001 Aug;131(8):2197-203
references.pmid: 11481417
references.citation: Cancer Res. 2003 Nov 1;63(21):7520-5
references.pmid: 14612554
references.citation: J Agric Food Chem. 2001 Dec;49(12):5743-9
references.pmid: 11743757
references.citation: Mol Cancer Ther. 2005 Apr;4(4):554-61
references.pmid: 15827328
references.citation: Mutat Res. 2007 May-Jun;635(2-3):90-104
references.pmid: 17134937
references.citation: Mol Cancer Ther. 2007 Mar;6(3):1013-21
references.pmid: 17339367
references.citation: Clin Interv Aging. 2006;1(1):11-31
references.pmid: 18047254
references.citation: Mutat Res. 1999 Sep;437(2):105-12
references.pmid: 10556615
references.citation: Curr Drug Targets. 2006 Apr;7(4):423-42
references.pmid: 16611030
references.citation: Mol Cancer Ther. 2006 Mar;5(3):637-44
references.pmid: 16546978